How I Rate AstraZeneca Plc As A ‘Buy And Forget’ Share

Is AstraZeneca plc (LON: AZN) a good share to buy and forget for the long term?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Right now I’m analysing some of the most popular companies in the FTSE 100 to establish if they are attractive long-term buy and forget investments.

Today I’m looking at AstraZeneca (LSE: AZN) (NYSE: AZN.US)

What is the sustainable competitive advantage?

At the end of 2012, AstraZeneca was one of the largest pharmaceutical companies in the world, employing over 50,000 people worldwide. Furthermore, AstraZeneca’s Crestor treatment is the world’s eighth bestselling drug, with sales of around $6.3bn.

Indeed, due to its size, AstraZeneca has a certain dominance over the biotechnology market, as many smaller competitors cannot compete with the firm’s financial power and research capabilities.  

Additionally, as AstraZeneca has exclusive production rights for its own treatments, the company can set prices, giving itself a wide profit margin. In particular, even after the loss of some exclusive manufacturing rights last year (which caused a 15% drop in revenue), AstraZeneca’s net profit margin still came in at 22%.

Having said that, AstraZeneca is facing fierce competition from generic producers, which are now manufacturing cheaper versions of some key drugs, after the company’s exclusive manufacturing rights expired last year.

Nonetheless, AstraZeneca’s size and global exposure mean that the company is able to stay ahead of the game, as the firm’s brand attracts talented personal.

Moreover, many larger pharmaceutical companies are now forming research partnerships, in an attempt to offset the stream of patent expirations that are affecting the industry.

Company’s long-term outlook?

With the spectre of disease always present, the demand for AstraZeneca’s products will remain constant, or even grow over the long term, as long as the company can produce treatments that are effective.

It appears that AstraZeneca is well placed to do this. Indeed, the firm has 84 new treatments under development, 13 of which are in the final stages of testing.

Furthermore, AstraZeneca has a strong balance sheet with net debt of only $2bn — a debt to asset ratio of 4%, giving the company plenty of room to acquire smaller competitors as well as new treatments for its pipeline.

Foolish summary

Overall, there will always be a strong demand for AstraZeneca’s products and the company has plenty of treatments under development that will allow it to stay ahead of the game. Additionally, with an almost debt free balance sheet, the company has plenty of room to spend for future growth.

So overall, I rate AstraZeneca as a very good share to buy and forget.

More FTSE opportunities

As well as AstraZeneca, I am also positive on the five FTSE shares highlighted within this exclusive wealth report.

Indeed, all five opportunities offer a mix of robust prospects, illustrious histories and dependable dividends, and have just been declared by the Fool as “5 Shares You Can Retire On“!

Just click here for the report — it’s free.

In the meantime, please stay tuned for my next FTSE 100 verdict

> Rupert does not own any share mentioned in this article.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

How I’d invest my first £20k ISA to target £4,900 a year from dividend shares

Looking for dividend shares in a new Stocks and Shares ISA, and want diversification too? Here's how I'd go about…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »